In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains
Related Experiment Videos
T Fernandes-Alnemri1, R C Armstrong, J Krebs
1Center for Apoptosis Research and the Kimmel Cancer Center Institute, Jefferson Medical College, Philadelphia, PA 19107, USA.
Abstract:
Emerging evidence suggests that an amplifiable protease cascade consisting of multiple aspartate specific cysteine proteases (ASCPs) is responsible for the apoptotic changes observed in mammalian cells undergoing programmed cell death. Here we describe the cloning of two novel ASCPs from human Jurkat T-lymphocytes. Like other ASCPs, the new proteases, named Mch4 and Mch5, are derived from single chain proenzymes. However, their putative active sites contain a QACQG pentapeptide instead of the QACRG present in ail known ASCPs. Also, their N termini contain FADD-like death effector domains, suggesting possible interaction with FADD. Expression of Mch4 in Escherichia coli produced an active protease that, like other ASCPs, was potently inhibited (Kj = 14 nM) by the tetrapeptide aldehyde DEVD-CHO. Interestingly, both Mch4 and the serine protease granzyme B cleave recombinant proCPP32 and proMch3 at a conserved IXXD-S sequence to produce the large and small subunits of the active proteases. Granzyme B also cleaves proMch4 at a homologous IXXD-A processing sequence to produce mature Mch4. These observations suggest that CPP32 and Mch3 are targets of mature Mch4 protease in apoptotic cells. The presence of the FADD-like domains in Mch4 and Mch5 suggests a role for these proteases in the Fas-apoptotic pathway. In addition, these proteases could participate in the granzyme B apoptotic pathways.
Insights
Two novel aspartate specific cysteine proteases (ASCPs), Mch4 and Mch5, were identified in human T-lymphocytes. These proteases possess unique active sites and FADD-like domains, suggesting roles in programmed cell death pathways.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Programmed cell death involves a protease cascade.
- Aspartate specific cysteine proteases (ASCPs) are key mediators of apoptosis.
- Mammalian cell apoptosis is regulated by complex protease networks.
Purpose of the Study:
- To clone and characterize novel ASCPs from human Jurkat T-lymphocytes.
- To investigate the enzymatic activity and substrate specificity of Mch4 and Mch5.
- To elucidate the potential roles of Mch4 and Mch5 in apoptotic pathways.
Main Methods:
- Cloning of Mch4 and Mch5 from human Jurkat T-lymphocytes.
- Expression of active Mch4 in Escherichia coli.
- Enzyme inhibition assays using DEVD-CHO.
- Cleavage assays with recombinant proCPP32, proMch3, and proMch4 using Mch4 and granzyme B.
Main Results:
- Two novel ASCPs, Mch4 and Mch5, were cloned, featuring unique QACQG active sites and FADD-like domains.
- Active Mch4 was produced in E. coli and inhibited by DEVD-CHO.
- Mch4 and granzyme B process proCPP32 and proMch3 into active proteases.
- Granzyme B processes proMch4 into its mature form, indicating cross-talk between pathways.
Conclusions:
- Mch4 and Mch5 are novel ASCPs with potential roles in Fas-mediated and granzyme B-mediated apoptosis.
- CPP32 and Mch3 are likely targets of Mch4 during apoptosis.
- The FADD-like domains suggest involvement in death receptor signaling pathways.